Background Reliable estimates of populations aff ected by diseases are necessary to guide effi cient allocation of public health resources. Sickle haemoglobin (HbS) is the most common and clinically signifi cant haemoglobin structural variant, but no contemporary estimates exist of the global populations aff ected. Moreover, the precision of available national estimates of heterozygous (AS) and homozygous (SS) neonates is unknown. We aimed to provide evidencebased estimates at various scales, with uncertainty measures.
Introduction
Sickle haemoglobin (HbS) is the most common pathological haemoglobin mutation worldwide. 1 This mutation is a structural variant of normal adult haemoglobin (HbA), which is inherited as a Mendelian trait. Carriers, or heterozygotes (AS individuals), inherit an HbS allele from one parent and an HbA allele from the other. These individuals are usually asymptomatic. Homozygotes (SS individuals) who have inherited HbS alleles from both parents suff er from sickle cell anaemia, which often leads to acute and chronic complications. 2 Without treatment, which is rarely available in low-income high-burden countries, it is assumed that most children born with the disease die in their fi rst years of life. 3 A map showing the global distribution of the HbS allele among indigenous populations has been published 4 and used for geographical confi rmation of the malaria hypothesis, which suggests that the gene responsible for sickle haemoglobin disorders could reach high frequencies because of the resistance conferred against malaria by the heterozygous carrier state. 5 This map does not, however, refl ect the contemporary distribution of the populations with the HbS allele. Following human diasporas, 6 the HbS allele has spread from the highly malarious regions (where it was selected for the resistance that it confers to malaria) to most other regions worldwide. 7 In low-income and middle-income countries, the epidemiological transition resulting from economic development and improve ments in hygiene, nutrition, and public health (including malaria control) has contributed to signifi cantly reduced infant and child mortality. 8 As a consequence, patients with HbS who would have previously died undiagnosed in their fi rst years of life can now survive into adulthood. 9 Despite substantial decreases in malaria endemicity worldwide 10 and hence reduced selection pressure for the HbS gene, population dynamics dictate that it would take many generations for HbS to reach allele fre quencies close to zero (for example 100 generations for an initial frequency of 0·06 and fi tness values of 1·0 and 0 for AS and SS individuals, respectively). 11 Additionally, the population growth rate is still relatively high in many countries with high frequencies of HbS so that, without prenatal diagnosis and avoidance strategies, 12 existing allele frequencies will lead to a progressive increase in the absolute number of SS neonates for many gener ations. In high-income coun tries, screening programmes are now commonly needed to diagnose HbS in mixed populations to provide counselling and to prevent serious clinical compli cations. 13 These factors strongly suggest that the number of AS and SS cases and associated care costs will substantially increase over the coming decades. 12, [14] [15] [16] In this context, reliable estimates of the populations aff ected by haemoglobin disorders are desirable to guide public-health priority settings. We aimed to develop a new cartographic method to provide global, regional, national, and subnational (in data-rich areas) estimates of AS and SS neonates accompanied by appropriate uncertainty measures. Our study generated the following products: (1) a contemporary georeferenced database of HbS allele frequency surveys, which will be made freely accessible online as part of the Malaria Atlas Project's Repository of Open Access Data (ROAD-MAP); (2) a Bayesian model-based geostatistical framework 17 that uses spatial data to predict allele frequencies in unsampled areas and pro duces a continuous global map of the contemporary distribution of HbS; (3) global, regional, national, and subnational annual estimates of HbS neonate heterozygotes and homozygotes with areal uncertainty predictions, 18 based on Hardy-Weinberg equilibrium 19, 20 and on the pairing of the allele frequency predictions with demographic data.
Methods

Database and contemporary map of HbS allele frequency
Online bibliographic searches were done to create a database of spatially located surveys of HbS allele frequency, supplemented by various unpublished datasets (fi gure 1). The temporal distribution and sample size of surveys are shown in the appendix pp 4-10. We excluded community surveys for which any selection bias (eg, ethnicity or health status) in the sampling methodology was stated or suspected. Remaining surveys were judged to be representative of the local populations and retained only if the sample size and the number of AS individuals (and SS individuals when given) were reported and they could be georeferenced to the district level (second administrative level) or below. 21 The input data for the model were geographic coordinates (latitude and long itude in decimal degrees) and the number of HbS and non-HbS alleles in the population samples. A Bayesian geostatistical model, described in detail previously, 4 was fi tted to the data and used to predict HbS allele frequencies at unsampled locations and generate continuous maps at 5×5 km resolution (appendix pp [10] [11] [12] [13] [14] [15] . Diff erences between these maps and the ones previously published 4 are further highlighted in the appendix pp 17. Validation metrics were calculated by com paring the observed allele frequency for a 10% random hold-out sample (a subset of the data removed from the validation analysis, so that the observed values can be compared with the predicted values) of the dataset with the prediction output created from the thinned 90% subset of the data (appendix pp [15] [16] [17] .
Defi ning estimates of neonates aff ected in 2010
We estimated the number of neonates aff ected in 2010 by combining our HbS allele frequency predictions with high-resolution population distribution data (fi gure 1) from the Global Rural Urban Mapping Project (GRUMP). 22 For each country, the crude birth rate for 2010-15 was downloaded from the 2010 online revision population database of the UN world population prospects 23 and combined with the population surfaces to estimate the total number of neonates expected in 2010 globally within each 5×5 km pixel (appendix pp [19] [20] .
Aggregating per-pixel HbS allele frequency predictions to subnational (for national fi rst-level subdivisions [ie, province or district, containing at least two datapoints]), national, regional, or global scales, while maintaining the correct statistical-dependence structure and therefore allowing these estimates to be calculated with appropriate credible intervals (CIs) 18 HbS), if x is the HbS allele frequency at a given pixel, x² and 2x (1-x) represent SS and AS frequencies, respectively. By integrating samples of these quantities from their PPDs over the area of interest, weighted by the population density and crude birth rate, we produced a PPD for the number of neonates aff ected, from which various summary estimates (eg, posterior mean or median) and CIs (eg, 95%) could be generated (appendix pp 20-22). WHO regional country groupings used previously 7 might not be the most useful for summarising HbS epidemiology, because of the variable clinical severity of the multiple HbS haplotypes 24 and its link with malaria endemicity. 25 We therefore present our results both within WHO regions and within modifi ed regional groupings, called HbS regions. The rationale for using modifi ed regions is described in more detail in the appendix pp 22-24.
Results
A total of 1211 spatially unique datapoints (fi gure 2) from 435 references (web dataset) matched all our inclusion criteria. Of these, 51% (619) were located in the African continent, 23% (273) in the Asian continent, 17% (203) in the Americas, 9% (112) in Europe, and <1% (four) in Oceania. Absence of HbS in the populations tested was recorded for 292 datapoints, of which 117 were in Asia, 86 in Africa, 69 in the Americas, 17 in Europe, and three in Oceania. 9 032 377 individuals were included in the selected surveys with overall sample sizes ranging from one to 3 212 374 individuals (appendix p 5). The mean overall sample size was 7458 (SD 105 542) individuals.
To our knowledge, the map presented here, illustrated by the mean of the PPD (fi gure 2), is the fi rst cartographic representation of the contemporary distribution of sickle haemoglobin globally. Although frequencies above 20% have been reported in small samples (<100) of specifi c ethnic groups, frequencies above 18% are unlikely according to the model at the population level. The maximum predicted median allele frequency was only identifi ed in one small patch in northern Angola. Predictions above 15% were commonly identifi ed in that area, as well as around the Gabon Estuary (Libreville) and in localised areas in southwestern Nigeria (Ibadan) and east of Lake Victoria. Predictions between 10·0% and 12·5% were found around the areas described above, in two patches in the south of the DR Congo and in southern Karnataka, India. Frequencies between 7·5% and 12·5% were predicted in large areas extending from southern Senegal to northern Liberia, and from southern Ghana to northern Zambia. Smaller areas of similar frequencies were predicted in Belize; in Khalkidhiki, Greece; in northeastern Côte d'Ivoire, northwestern Egypt, south of Lake Chad, in central Sudan, around Lake Victoria and the coast of Kenya, Tanzania, and Mozambique, and on the east coast of Madagascar; in southern Turkey, southwestern Syria and eastern Saudi Arabia; and in Karnataka, Chhattisgarh, and Orissa in India. The maximum predicted frequency in South America was about 5%. Predicted median frequen cies in western Europe and localised patches in North America (California, Mississippi, or Alabama) did not exceed 1%. By contrast with the high HbS allele frequencies predicted across most of sub-Saharan Africa, large areas where HbS is generally absent were identifi ed in the south and Horn of Africa, as well as in Morocco and Algeria.
The highest uncertainties in predicted allele frequencies were seen in the western area of the DR Congo and in northwestern Angola, where predictions ranged between 3% and 14%, corresponding to an IQR of 11% (fi gure 2). Relatively high uncertainties (IQR ≥7·5%) were seen across most of sub-Saharan Africa and in parts of Egypt and Libya; in eastern Cuba, Nicaragua and Honduras; in eastern Saudi Arabia; and in Karnataka, India. The maximum IQRs in North America and South America were 5% and 7%, respectively. Uncertainty up to 7% was also seen in parts of Greece (1-8%), Syria (0-7%, 1-8%, and 2-9%, in diff erent parts of the country), and Lebanon (2-9%).
Comparison of the PPD predicted from the thinned dataset with the known values at the locations from the hold-out subset revealed a minimal overall bias, with a mean error in allele frequency prediction of 0·2%. The mean absolute error, which measures the average magnitude of allele frequency prediction errors, was 3·0%. The predicted allele frequencies are therefore only slightly overestimated (ie, mean errors were mostly small and positive), but predicted HbS allele frequencies could be substantially diff erent from the observed values (ie, absolute errors up to 12·5% locally), especially in areas with a high short-range heterogeneity in the data and where the distribution of the dataset was patchy (appendix pp [15] [16] [17] .
Pairing demographic data with our predicted allele frequencies, we estimated that, in 2010, 312 302 (IQR 294 307-329 729) homozygous SS babies and 5 476 407 (IQR 5 290 779-5 679 288) heterozygous AS babies were born globally (table 1); the total number of neonates aff ected was 5 788 709 (IQR 5 585 086-6 009 017). At the regional scale, 64·4% of the AS neonates were from sub-Saharan Africa, 22·7% in the Arab-India region, 7·4% in 
Discussion
Sickle cell anaemia has recently been recognised as a global public health problem by the UN and WHO. 26 The burden of this disorder and other haemoglobin disorders is expected to increase in the coming decades, because of reductions in infant mortality in many lowincome countries and increasing migration from high to low HbS-frequency areas worldwide. 12 A detailed assess ment of our current epidemiological knowledge and of the magnitude of the problem is needed to defi ne ad equate policies for diagnostics, education, and treatment to prevent or manage complications associated with sickle cell anaemia. We believe that the fi rst contemporary global map of the distribution of sickle haemoglobin (fi gure 2) and derived global, regional, national, and subnational annual estimates with given precision of AS and SS neonates presented in our report represent substantial contributions towards this goal (tables 1, 2; appendix pp 29-44; panel). The best way to reliably assess the situation would gen erally be through universal national neonate screening. 29 However, such programmes are rare, especially in areas with high HbS frequencies (appendix pp [25] [26] . Using existing survey data, combined with bespoke mapping and modelling methods, our aim was not only to update previous estimates 7 but also to take into account the striking geographical variation both in the availability of survey data, and in the frequency of HbS between and within populations, and to assess the reliability of our estimates.
Our map shows that high frequencies of HbS (>10%) are almost exclusively encountered in sub-Saharan Africa (fi gure 2). The areas of highest frequency in Africa seem to refl ect the origins of the diff erent African haplotypes Table 2 : Summary of regional annual predicted estimates of HbAS and HbSS neonates N i g e r i a D R C o n g o T a n z a n i a U g a n d a A n g o la C a m e r o o n Z a m b i a G h a n a G u i n e a N i g e r S u d a n B e n i n K e n y a T u r k m e n i s t a n A z e r b a i j a n S w e d e n N o r w a y K a z a k h s t a n U z b e k i s t a n A r m e n i a B e la r u s G e o r g i a T a j i k i s t a n L i t h u a n i a K y r g y z s t a n L a t v i a F i n la n d E s t o n i a I c e la n d (Senegal, Benin, and Central African Republic or Bantu). 30 Frequencies of HbS seem highly heterogeneous across the Indian subcontinent. HbS is still rare in southeast Asian populations. In the Americas, the distribution of HbS, which is common in populations along the eastern coast of the continents, mirrors the distribution of African Americans. Uncertainties were highest in areas for which no data were available, such as central DR Congo (fi gure 2). Data in those areas would be particularly useful to improve our knowledge of the distribution of this gene. Our validation process showed that our model performed well in view of the amount of data available.
Micromapping studies have shown that HbS frequency can greatly vary over short distances. 31 We present the fi rst evidence-based estimates with precision measures, accounting for these spatial heterogeneities (where data permits) and demographic factors. Our model-based predictions showed large diff erences at the national level when compared with previous estimates (appendix pp 29-33, 45-48). 7 Most neonates with HbS are born within specifi c regions in Nigeria, DR Congo, and India (fi gures 3-5, appendix pp [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Health interventions (eg, screening pro gramme, genetic counselling) in those regions would, therefore, have the greatest eff ect on total numbers of aff ected neonates.
Due to the kinetics of inherited disorders, the current and future public health challenges are twofold. First, countries with high HbS allele frequencies need to be prepared to provide health care for patients with sickle cell anaemia. With substantial reductions in mortality of children younger than 5 years of age in many lowincome countries, 8 SS neonates who would have previously died undiagnosed are now more likely to survive to adulthood. These countries, therefore, need to know the extent of the problem and to plan effi cient and aff ordable treatment policies to reduce the morbidity of these patients during their lifetime. 9 Second, although AS individuals are usually asymptomatic, it is important to educate carriers about their status to try to prevent the future birth of homozygous children, as well as to avoid psychosocial issues (eg, miscon ceptions or stigma tisation). 32 Such education programmes are needed not only in low-income countries but also in high-income countries.
Without a universal neonate screening programme and eff ective data aggregation and analysis systems (appendix pp [25] [26] , it is impossible to know with exact precision the number of neonates aff ected by HbS (or any other inherited disorder) within a given country. Pilot screening programmes are under way in several African countries and India, which should help update our knowledge of the current distribution of HbS and refi ne our estimates in many areas. Better accessibility to data in high-income countries (eg, USA and UK) would also be valuable.
While the approach presented in our report represents a substantial advance in both the methodology and underlying evidence base compared with earlier attempts to quantify global estimates of neonates aff ected by sickle haemoglobin, 7 several limitations remain. These limitations include the scarcity or accessibility of information about HbS allele frequency in some important areas; the presence of confounding factors such as non-random mating; and the interactions with other inherited blood disorders. Contemporary HbS allele frequency heterogeneity over short distances and between ethnic groups can only partly be explained by the selection pressure of malaria, especially in India. 4 Other factors, such as environmental variables (eg, altitude) or diff erences in social behaviour (eg, consanguinity or endogamy) 33 also contribute to HbS allele frequency. For various reasons, including ethical issues and the diffi culty of defi ning an ethnic group, such social factors are not consistently reported in HbS surveys. Therefore, cap turing spatial variations in these factors from a partial dataset is diffi cult. As a consequence, the inclusion of ethnic origin or consanguinity would probably have added uncertainty to the model. Moreover, no consistent high-resolution global database of these factors is currently available. Defi ning a minimum standard of information gathered and reported for new surveys (eg, sampling method, location, age group) would greatly facilitate such global studies.
Finally, our study focuses on AS and SS neonates. We are aware that these estimates only represent part of the burden caused by HbS. First, we have calculated neonate estimates, not all-age population estimates or disabilityadjusted life year losses from HbS. 1 The feasibility of calculating such estimates is currently very limited because of a general paucity of information on the variations of clinical severity between haplotypes, and on mortality caused by HbS, both in low-income and high-income countries. 34 Second, our estimates do not include individuals with compound disorders such as haemoglobin SC disease or haemoglobin S-beta thalassaemia disease. Including these individuals would require a good knowledge of the distribution of haemoglobin C and β-thalassaemia, as well as of the interactions between these variants. Recent studies have shown that such interactions, or epistatic eff ects, are complex. 35, 36 Unless similar rigorous quantitative methods are used to study related disorders and HbS mortality, reliable estimates of the general economic and public health burden of haemoglobinopathies as a whole will be impossible to produce.
Having been neglected for decades, awareness of HbS and of its burden on public health services globally is fi nally growing. Our study aimed to make optimal use of existing data to create a contemporary map of HbS allele frequency and calculate annual estimates of AS and SS neonates at various spatial scales. The global quantitative map presented here shows for the fi rst time the contemporary distribution of HbS. Our estimates and associated precision measures provide a valuable result to guide public health decisions at various scales and to assess future changes.
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Panel: Research in context
Systematic review
We searched PubMed, ISI Web of Knowledge, and Scopus, for articles including epidemiological data on HbS allele frequency. We used strict inclusion criteria regarding the sampling and diagnostic methods, as well as the precision of the study location, but no restriction was applied for the publication year or the sample size. We also contacted study investigators and experts in the fi eld either to clarify some information or to complement our database with unpublished data. All selected surveys were included in our global database. Our Bayesian geostatistical model accounted for uncertainty associated with the input data and produced precision measures. Further details are given in the appendix pp 3-18.
Interpretation
Few studies have attempted to quantify the burden of HbS. In 2001, Weatherall and colleagues 1 estimated that about 216 000 babies were born with sickle cell anaemia in Africa, and between 60 000 and 100 000 outside of Africa. In 2007, using a partially updated version of Livingstone's database, 27 Modell and Darlison 7 calculated global, regional, and national annual estimates of babies born with sickle cell anaemia, but only some results have been published. Moreover, the method was based on crude national averages of datasets assembled with less strict inclusion criteria; the precision of these estimates is unknown. Using data from the 2003 United Nations Demographic Yearbook, Modell and Darlison estimated that 222 785 babies were born with sickle cell anaemia globally. 7,28 Their regional and national estimates are shown in table 2 and fi gures 3-5, respectively. Our study is, therefore, the fi rst rigorous evidence-based analysis focusing on sickle haemoglobin and using a contemporary dataset combined with demographic data and modern geostatistical modelling techniques that account for spatial heterogeneities and provide precision measures.
